{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:51:24Z","timestamp":1777909884887,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate factors affecting relapse and remission in patients with Beh\u00e7et uveitis (BU) in the context of using the interferon alpha2a (IFN\u03b12a) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinical records were reviewed of 32 patients (totaling 54 eyes) presenting with severe BU who had been treated with IFN\u03b12a therapy. Factors influencing relapsing-remitting course of BU during IFN\u03b12a therapy and after the cessation of the agent were evaluated. Possible affecting factors of recurrence were age, gender, duration of the Beh\u00e7et disease, time elapsed before starting the drug, number of relapses before the starting of IFN\u03b12a, laterality, and presence of panuveitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty patients (93.7%) responded to IFN\u03b12a therapy. Annual attack rate before and after IFN\u03b12a treatment was determined to be 4.03\u2009\u00b1\u20093.19 (attack per year) and 0.58\u2009\u00b1\u20091.07, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In univariable statistical evaluation, women tended to have a lower relapse risk than men. Multivariable analyses showed that age was the major factor determining relapse rate, while the effect of gender was not statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.196). The other probable influencing factors were not found to be statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Increase in visual acuity observed during last examination compared to initial examination was determined to be statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.018).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Even if the female gender was evaluated as a good prognostic factor in univariable analyses, it was not assessed as an effective prognostic factor in multivariable analyses. Being aged may be regarded a good prognostic factor on the relapsing-remitting course of patients with BU who were treated with IFN\u03b12a therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2018.0083","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T16:05:51Z","timestamp":1540483551000},"page":"58-65","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Factors Affecting Relapse and Remission in Beh\u00e7et's Uveitis Treated with Interferon Alpha2a"],"prefix":"10.1177","volume":"35","author":[{"given":"Hande","family":"Celiker","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Marmara University School of Medicine, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haluk","family":"Kazokoglu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Marmara University School of Medicine, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"1152","article-title":"\u00dcber rezidivierende aphth\u00f6se durch ein virus verursachte Geschw\u00fcre am Mund, am Auge, und an den Genitalien","volume":"105","author":"Beh\u00e7et H.","year":"1937","unstructured":"Beh\u00e7et H. \u00dcber rezidivierende aphth\u00f6se durch ein virus verursachte Geschw\u00fcre am Mund, am Auge, und an den Genitalien. Dermatol. Wochenschr. 105:1152\u20131157, 1937.","journal-title":"Dermatol. Wochenschr"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2007.09.002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(82)90079-0"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.866257"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3318-6"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.03.022"},{"key":"e_1_3_2_9_2","first-page":"343","article-title":"[Ocular prognosis in Beh\u00e7et's disease]","volume":"15","author":"Cochereau-Massin I.","year":"1992","unstructured":"Cochereau-Massin I., , Wechsler B., , Le Hoang P., et al. [Ocular prognosis in Beh\u00e7et's disease]. J. Fr. Ophtalmol. 15:343\u2013347, 1992.","journal-title":"J. Fr. Ophtalmol"},{"key":"e_1_3_2_10_2","first-page":"592","article-title":"[Ophthalmological involvement in Beh\u00e7et disease","volume":"20","author":"El Belhadji M.","year":"1997","unstructured":"El Belhadji M., , Hamdani M., , Laouissi N., , Zaghloul K., , Amraoui A., , and Benamour S. [Ophthalmological involvement in Beh\u00e7et disease. Apropos of 520 cases]. J. Fr. Ophtalmol., 20:592\u2013598, 1997.","journal-title":"Apropos of 520 cases]. J. Fr. Ophtalmol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.1997.tb00638.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1998.00159.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.5.488"},{"key":"e_1_3_2_14_2","first-page":"1437","article-title":"Complete regression of retinal neovascularisation after therapy with interferon in Behcet's disease [letter]","volume":"84","author":"Stubiger N.","year":"2000","unstructured":"Stubiger N., , Kotter I., , and Zierhut M. Complete regression of retinal neovascularisation after therapy with interferon in Behcet's disease [letter]. Br. J. Ophthalmol. 84:1437\u20131438, 2000.","journal-title":"Br. J. Ophthalmol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.8.4.293.6453"},{"key":"e_1_3_2_16_2","first-page":"768","article-title":"Behcet's disease: uveitis-therapy with interferon alpha2a\u2014prospective clinical study in 33 patients","volume":"218","author":"St\u00fcbiger N.","year":"2001","unstructured":"St\u00fcbiger N., , K\u00f6tter I., , Deuter C., , and Zierhut M. Behcet's disease: uveitis-therapy with interferon alpha2a\u2014prospective clinical study in 33 patients. Klin. Monbl. Augenheilkd. 218:768\u2013773, 2001.","journal-title":"Klin. Monbl. Augenheilkd"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0346-y"},{"key":"e_1_3_2_18_2","first-page":"1078","article-title":"International Study Group for Beh\u00e7et's Disease","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et's disease","year":"1990","unstructured":"Criteria for diagnosis of Beh\u00e7et's disease. International Study Group for Beh\u00e7et's Disease. Lancet. 335:1078\u20131080, 1990.","journal-title":"Lancet"},{"key":"e_1_3_2_19_2","first-page":"509","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group","volume":"140","author":"Jabs D.A.","year":"2005","unstructured":"Jabs D.A., , Nussenblatt R.B., , and Rosenbaum J.T.; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am. J. Ophthalmol. 140:509\u2013516, 2005.","journal-title":"Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am. J. Ophthalmol"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.038"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.04.009"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27581"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0238"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1206204"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.022"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0719-0"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1133835"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231"},{"key":"e_1_3_2_29_2","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno S.","year":"2004","unstructured":"Ohno S., , Nakamura S., , Hori S., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis. J. Rheumatol. 31:1362\u20131368, 2004.","journal-title":"J. Rheumatol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-003-0927-7"},{"key":"e_1_3_2_31_2","first-page":"896","article-title":"Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et's disease treated with interferon-alpha-2a","volume":"35","author":"Krause L.","year":"2008","unstructured":"Krause L., , Altenburg A., , Pleyer U., , Kohler A.K., , Zouboulis C.C., , and Foerster M.H. Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et's disease treated with interferon-alpha-2a. J. Rheumatol. 35:896\u2013903, 2008.","journal-title":"J. Rheumatol"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2008.69.10.31317"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.09.010"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-005-0005-8"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.032"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3318-6"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)31022-6"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2018.0083","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:42:44Z","timestamp":1777646564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2018.0083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,1]]}},"alternative-id":["10.1089\/jop.2018.0083"],"URL":"https:\/\/doi.org\/10.1089\/jop.2018.0083","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]}}}